Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...

A growing body of research and experts have suggested that GLP-1s can be powerful tools for midlife women. Here’s what we ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

A recent study found that Glucagon-like peptide-1 (GLP-1) receptor agonist use in hypertrophic cardiomyopathy (HCM) patients ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs (hazard ratios, 1.39 and 1.25 for semaglutide and liraglutide, respectively). HealthDay ...

Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes. (HealthDay News) — For adults with diabetes and obesity, glucagon-like ...

Type 2 diabetes is a recognized risk factor for vertebral fractures, which can lead to long-term disability and increased ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss. Objective: Obesity affects more than 40 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced risk for obesity-related ...